Phio Pharmaceuticals Corp. (PHIO)
Develops cancer-fighting drugs that silence genes in immune and tumor cells.
$1.02-0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-56.2%
The outlook
PHIO trades at $1.02, near the bottom of its 52-week range and below both its 50- and 200-day moving averages, suggesting a weak near-term trend. The single analyst covering the stock rates it a Strong Buy with an average price target implying substantial upside, though thin coverage limits the reliability of that consensus. Overall sentiment is neutral, reflecting the stock's depressed price alongside the optimistic analyst view.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 1 analysts
Price trendBelow its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Price targetAvg target +1273% vs current price
Market cap
$11.8M
52-wk high
$4.19
52-wk low
$0.81
50-day avg
$1.06
200-day avg
$1.25
Trailing P/E
—